- Home
- CHRS vs ELTX Comparison
CHRS vs ELTX Comparison
Compare CHRS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ELTX
- Stock Information
- Founded
- CHRS 2010
- ELTX 2011
- Country
- CHRS United States
- ELTX United States
- Employees
- CHRS N/A
- ELTX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- ELTX Health Care
- Exchange
- CHRS Nasdaq
- ELTX Nasdaq
- Market Cap
- CHRS 186.0M
- ELTX 158.5M
- IPO Year
- CHRS 2014
- ELTX N/A
- Fundamental
- Price
- CHRS $1.11
- ELTX $8.15
- Analyst Decision
- CHRS Strong Buy
- ELTX Strong Buy
- Analyst Count
- CHRS 4
- ELTX 1
- Target Price
- CHRS $4.51
- ELTX $13.00
- AVG Volume (30 Days)
- CHRS 1.4M
- ELTX 108.3K
- Earning Date
- CHRS 11-06-2025
- ELTX 11-13-2025
- Dividend Yield
- CHRS N/A
- ELTX N/A
- EPS Growth
- CHRS N/A
- ELTX N/A
- EPS
- CHRS 1.34
- ELTX N/A
- Revenue
- CHRS $277,728,000.00
- ELTX N/A
- Revenue This Year
- CHRS N/A
- ELTX N/A
- Revenue Next Year
- CHRS $109.48
- ELTX N/A
- P/E Ratio
- CHRS $0.82
- ELTX N/A
- Revenue Growth
- CHRS 152.07
- ELTX N/A
- 52 Week Low
- CHRS $0.71
- ELTX $4.60
- 52 Week High
- CHRS $2.43
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- CHRS 31.08
- ELTX 25.46
- Support Level
- CHRS $1.09
- ELTX $7.87
- Resistance Level
- CHRS $1.25
- ELTX $8.99
- Average True Range (ATR)
- CHRS 0.13
- ELTX 0.52
- MACD
- CHRS -0.04
- ELTX -0.06
- Stochastic Oscillator
- CHRS 0.81
- ELTX 13.10
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.